These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 32845842)

  • 1. Identifying Gene Signatures for Cancer Drug Repositioning Based on Sample Clustering.
    Wang F; Ding Y; Lei X; Liao B; Wu FX
    IEEE/ACM Trans Comput Biol Bioinform; 2022; 19(2):953-965. PubMed ID: 32845842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statistically controlled identification of differentially expressed genes in one-to-one cell line comparisons of the CMAP database for drug repositioning.
    He J; Yan H; Cai H; Li X; Guan Q; Zheng W; Chen R; Liu H; Song K; Guo Z; Wang X
    J Transl Med; 2017 Sep; 15(1):198. PubMed ID: 28962576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human Protein Complex-Based Drug Signatures for Personalized Cancer Medicine.
    Wang F; Ding Y; Lei X; Liao B; Wu FX
    IEEE J Biomed Health Inform; 2021 Nov; 25(11):4079-4088. PubMed ID: 34665747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of batch effect correction methods on drug induced differential gene expression profiles.
    Zhou W; Koudijs KKM; Böhringer S
    BMC Bioinformatics; 2019 Aug; 20(1):437. PubMed ID: 31438848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A two-tiered unsupervised clustering approach for drug repositioning through heterogeneous data integration.
    Hameed PN; Verspoor K; Kusljic S; Halgamuge S
    BMC Bioinformatics; 2018 Apr; 19(1):129. PubMed ID: 29642848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug Repositioning for Cancer Therapy Based on Large-Scale Drug-Induced Transcriptional Signatures.
    Lee H; Kang S; Kim W
    PLoS One; 2016; 11(3):e0150460. PubMed ID: 26954019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New drug candidates for treatment of atypical meningiomas: An integrated approach using gene expression signatures for drug repurposing.
    Zador Z; King AT; Geifman N
    PLoS One; 2018; 13(3):e0194701. PubMed ID: 29558515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Review of Drug Repositioning Based Chemical-induced Cell Line Expression Data.
    Wang F; Lei X; Wu FX
    Curr Med Chem; 2020; 27(32):5340-5350. PubMed ID: 30381060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcriptomic Data Mining and Repurposing for Computational Drug Discovery.
    Wang Y; Yella J; Jegga AG
    Methods Mol Biol; 2019; 1903():73-95. PubMed ID: 30547437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Personalised drug repositioning for Clear Cell Renal Cell Carcinoma using gene expression.
    Koudijs KKM; Terwisscha van Scheltinga AGT; Böhringer S; Schimmel KJM; Guchelaar HJ
    Sci Rep; 2018 Mar; 8(1):5250. PubMed ID: 29588458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DMAP: a connectivity map database to enable identification of novel drug repositioning candidates.
    Huang H; Nguyen T; Ibrahim S; Shantharam S; Yue Z; Chen JY
    BMC Bioinformatics; 2015; 16 Suppl 13(Suppl 13):S4. PubMed ID: 26423722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Accurate Drug Repositioning through Non-tissue-Specific Core Signatures from Cancer Transcriptomes.
    Xu C; Ai D; Shi D; Suo S; Chen X; Yan Y; Cao Y; Zhang R; Sun N; Chen W; McDermott J; Zhang S; Zeng Y; Han JJ
    Cell Rep; 2018 Oct; 25(2):523-535.e5. PubMed ID: 30304690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Proteotranscriptomic-Based Computational Drug-Repositioning Method for Alzheimer's Disease.
    Lee SY; Song MY; Kim D; Park C; Park DK; Kim DG; Yoo JS; Kim YH
    Front Pharmacol; 2019; 10():1653. PubMed ID: 32063857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Computational Drug Repositioning for Gastric Cancer using Reversal Gene Expression Profiles.
    Kim IW; Jang H; Kim JH; Kim MG; Kim S; Oh JM
    Sci Rep; 2019 Feb; 9(1):2660. PubMed ID: 30804389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Computational drug repositioning through heterogeneous network clustering.
    Wu C; Gudivada RC; Aronow BJ; Jegga AG
    BMC Syst Biol; 2013; 7 Suppl 5(Suppl 5):S6. PubMed ID: 24564976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identifying prognostic features by bottom-up approach and correlating to drug repositioning.
    Li W; Yu J; Lian B; Sun H; Li J; Zhang M; Li L; Li Y; Liu Q; Xie L
    PLoS One; 2015; 10(3):e0118672. PubMed ID: 25738841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cogena, a novel tool for co-expressed gene-set enrichment analysis, applied to drug repositioning and drug mode of action discovery.
    Jia Z; Liu Y; Guan N; Bo X; Luo Z; Barnes MR
    BMC Genomics; 2016 May; 17():414. PubMed ID: 27234029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decoding Connectivity Map-based drug repurposing for oncotherapy.
    Zhao Y; Chen X; Chen J; Qi X
    Brief Bioinform; 2023 May; 24(3):. PubMed ID: 37068308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting associations among drugs, targets and diseases by tensor decomposition for drug repositioning.
    Wang R; Li S; Cheng L; Wong MH; Leung KS
    BMC Bioinformatics; 2019 Dec; 20(Suppl 26):628. PubMed ID: 31839008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An integrative approach using real-world data to identify alternative therapeutic uses of existing drugs.
    Hosomi K; Fujimoto M; Ushio K; Mao L; Kato J; Takada M
    PLoS One; 2018; 13(10):e0204648. PubMed ID: 30300381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.